These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26059076)

  • 21. Active surveillance: the Canadian experience.
    Klotz L
    Curr Opin Urol; 2012 May; 22(3):222-30. PubMed ID: 22453335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
    Krakowsky Y; Loblaw A; Klotz L
    J Urol; 2010 Jul; 184(1):131-5. PubMed ID: 20478589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention?
    Coen JJ; Feldman AS; Smith MR; Zietman AL
    BJU Int; 2011 May; 107(10):1582-6. PubMed ID: 20860650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy.
    Zietman AL; Thakral H; Wilson L; Schellhammer P
    J Urol; 2001 Nov; 166(5):1702-6. PubMed ID: 11586206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
    Roemeling S; Roobol MJ; Postma R; Gosselaar C; van der Kwast TH; Bangma CH; Schröder FH
    Eur Urol; 2006 Sep; 50(3):475-82. PubMed ID: 16713065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Active surveillance can reduce overtreatment in patients with low-risk prostate cancer.
    Thomsen FB; Røder MA; Hvarness H; Iversen P; Brasso K
    Dan Med J; 2013 Feb; 60(2):A4575. PubMed ID: 23461989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
    Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
    BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
    W V Med J; 2005; 101(4):168-71. PubMed ID: 16296198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study.
    Bul M; Zhu X; Valdagni R; Pickles T; Kakehi Y; Rannikko A; Bjartell A; van der Schoot DK; Cornel EB; Conti GN; Boevé ER; Staerman F; Vis-Maters JJ; Vergunst H; Jaspars JJ; Strölin P; van Muilekom E; Schröder FH; Bangma CH; Roobol MJ
    Eur Urol; 2013 Apr; 63(4):597-603. PubMed ID: 23159452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.
    Choo R; Klotz L; Danjoux C; Morton GC; DeBoer G; Szumacher E; Fleshner N; Bunting P; Hruby G
    J Urol; 2002 Apr; 167(4):1664-9. PubMed ID: 11912384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Percentage of cancer involvement in positive cores can predict unfavorable disease in men with low-risk prostate cancer but eligible for the prostate cancer international: active surveillance criteria.
    Russo GI; Cimino S; Castelli T; Favilla V; Urzì D; Veroux M; Madonia M; Morgia G
    Urol Oncol; 2014 Apr; 32(3):291-6. PubMed ID: 24184119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results of a surgically derived nomogram to predict Gleason score upgrading applied to a cohort of patients with "favorable-risk" prostate cancer treated with permanent seed brachytherapy.
    Bowes D; Crook JM; Wallace K; Evans A; Toi A; Finelli A; Jewett MA; Fleshner N; Catton C
    Urology; 2012 Sep; 80(3):649-55. PubMed ID: 22698474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in Gleason score grading on serial follow-up biopsies in prostate cancer patients undergoing active surveillance.
    Guijarro A; Hernández V; López B; Capitán C; Pérez-Fernández E; de la Peña E; de la Morena JM; Llorente C
    Actas Urol Esp; 2015 Apr; 39(3):139-43. PubMed ID: 25305107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncologic control obtained after radical prostatectomy in men with a pathological Gleason score ≥ 8: a single-center experience.
    Audenet F; Comperat E; Seringe E; Drouin SJ; Richard F; Cussenot O; Bitker MO; Rouprêt M
    Urol Oncol; 2011; 29(6):602-7. PubMed ID: 19926312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols.
    Iremashvili V; Pelaez L; Manoharan M; Jorda M; Rosenberg DL; Soloway MS
    Eur Urol; 2012 Sep; 62(3):462-8. PubMed ID: 22445138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
    Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
    Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.